Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Value of Sentinel Lymph Node Biopsy in Breast Cancer Surgery with Simple Pathology Facilities -An Iranian Local Experience with a Review of Potential Causes of False Negative Results

  • Amoui, Mahasti (Cancer Research Center, Shohadae Tajrish Hospital, Shahid Beheshti University of Medical Sciences) ;
  • Akbari, Mohammad Esmail (Cancer Research Center, Shohadae Tajrish Hospital, Shahid Beheshti University of Medical Sciences) ;
  • Tajeddini, Araam (Cancer Research Center, Shohadae Tajrish Hospital, Shahid Beheshti University of Medical Sciences) ;
  • Nafisi, Nahid (Cancer Research Center, Shohadae Tajrish Hospital, Shahid Beheshti University of Medical Sciences) ;
  • Raziei, Ghasem (Cancer Research Center, Shohadae Tajrish Hospital, Shahid Beheshti University of Medical Sciences) ;
  • Modares, Seyed Mahdi (Khatam Hospital) ;
  • Hashemi, Mohammad (Khatam Hospital)
  • Published : 2012.11.30
Download PDF
⟨ Previous Next ⟩

Abstract

Introduction: Sentinel lymph node biopsy (SLNB) is a precise procedure for lymphatic staging in early breast cancer. In a valid SLNB procedure, axillary lymph node dissection (ALND) can be omitted in nodenegative cases without compromising patient safety. In this study, detection rate, accuracy and false negative rate of SLNB for breast cancer was evaluated in a setting with simple modified conventional pathology facilities without any serial sectioning or immunohistochemistry. Material and Medthod: Patients with confirmed breast cancer were enrolled in the study. SLNB and ALND were performed in all cases. Lymph node metastasis was evaluated in SLN and in nodes removed by ALND to determine the false negative rate. Pathologic assessment was carried out only by modified conventional technique with only 3 sections. Detection rate was determined either by lymphoscintigraphy or during surgery. Results: 78 patients with 79 breast units were evaluated. SLN was detected in 75 of 79 cases (95%) in lymphoscintigraphy and 76 of 79 cases (96%) during surgery. SLN metastases was detected in 30 of 75 (40%) cases either in SLNB and ALND groups. Accuracy of SLNB method for detecting LN metastases was 92%. False negative rate was 3 of 30 of positive cases: 10%. In 7 of 10 cases with axillary lymphadenopathy, LN metastastates was detected. Conclusion: SLNB is recommended for patients with various tumor sizes without palpable lymph nodes. In modified conventional pathologic examination of SLNs, at least macrometastases and some micrometastases could be detected similar to ALND. Consequently, ALND could be omitted in node-negative cases with removal of all palpable LNs. We conclude that SLNB, as one of the most important developments in breast cancer surgery, could be expanded even in areas without sophisticated pathology facilities.

Keywords

References

  1. Abdollahi A, Jangjoo A, Dabbagh Kakhki VR, et al (2010). Factors affecting sentinel lymph node detection failure in breast cancer patients using intradermal injection of the tracer. Rev Esp Med Nucl, 29, 73-7. https://doi.org/10.1016/j.remn.2009.10.001
  2. Ashikaga T, Krag DN, Land SR, et al (2010). Morbidity results from the NSABP B-32 trial comparing sentinel lymph node dissection versus axillary dissection. J Surg Oncol, 102, 111-8. https://doi.org/10.1002/jso.21535
  3. Blamey RW, Hornmark-Stenstam B, Ball G, et al (2010). ONCOPOOL -a European database for 16,944 cases of breast cancer. Eur J Cancer, 46, 56-71. https://doi.org/10.1016/j.ejca.2009.09.009
  4. Brenot-Rossi I, Houvenaeghel G, Jacquemier J, et al (2003). Nonvisualization of axillary sentinel node during lymphoscintigraphy: is there a pathologic significance in breast cancer? J Nucl Med, 44, 1232-7.
  5. Carmon M, Olsha O, Rivkin L, et al (2006). Intraoperative palpation for clinically suspicious axillary sentinel lymph nodes reduces the false-negative rate of sentinel lymph node biopsy in breast cancer. Breast J, 12, 199-201. https://doi.org/10.1111/j.1075-122X.2006.00241.x
  6. Clarke D, Newcombe RG, Mansel RE (2004). The learning curve in sentinel node biopsy: the ALMANAC experience. Ann Surg Oncol, 11, 211-5. https://doi.org/10.1245/ASO.2004.12.924
  7. Cox CE, Kiluk JV, Riker AI (2008). significance of sentinel lymph node micrometastases in human breast cancer. J Am Coll Surg, 206, 261-8. https://doi.org/10.1016/j.jamcollsurg.2007.08.024
  8. Del Bianco P, Zavagno G, Burelli P, et al (2008). Morbidity comparison of sentinel lymph node biopsy versus conventional axillary lymph node dissection for breast cancer patients: results of the sentinella-GIVOM Italian randomised clinical trial. Eur J Surg Oncol, 34, 508-13. https://doi.org/10.1016/j.ejso.2007.05.017
  9. Fisher B, Jeong JH, Anderson S, et al (2002). Twenty-fiveyear follow-up of a randomized trial comparing radical mastectomy, total mastectomy, and total mastectomy followed by irradiation. N Engl J Med, 347, 567-75. https://doi.org/10.1056/NEJMoa020128
  10. Fleissig A, Fallowfield LJ, Langridge CI, et al (2006). Postoperative arm morbidity and quality of life. Results of the ALMANAC randomised trial comparing sentinel node biopsy with standard axillary treatment in the management of patients with early breast cancer. Breast Cancer Res Treat, 95, 279-93. https://doi.org/10.1007/s10549-005-9025-7
  11. Galimberti V (2006). International Breast Cancer Study Group Trial of sentinel node biopsy. J Clin Oncol, 24, 210-1. https://doi.org/10.1200/JCO.2005.04.5658
  12. Gill G (2009). Sentinel-lymph-node-based management or routine axillary clearance? One-year outcomes of sentinel node biopsy versus axillary clearance (SNAC): a randomized controlled surgical trial. Ann Surg Oncol, 16, 266-75. https://doi.org/10.1245/s10434-008-0229-z
  13. Giuliano AE, Hawes D, Ballman KV, et al (2011). Association of occult metastases in sentinel lymph nodes and bone marrow with survival among women with early-stage invasive breast cancer. Jama, 306, 385-93. https://doi.org/10.1001/jama.2011.1034
  14. Goyal A, Newcombe RG, Chhabra A, Mansel RE (2006). Factors affecting failed localisation and false-negative rates of sentinel node biopsy in breast cancer--results of the ALMANAC validation phase. Breast Cancer Res Treat, 99, 203-8. https://doi.org/10.1007/s10549-006-9192-1
  15. Hinson JL, McGrath P, Moore A, et al (2008). The critical role of axillary ultrasound and aspiration biopsy in the management of breast cancer patients with clinically negative axilla. Ann Surg Oncol, 15, 250-5. https://doi.org/10.1245/s10434-007-9524-3
  16. Husarik DB, Steinert HC (2007). Single-photon emission computed tomography/computed tomographyfor sentinel node mapping in breast cancer. Semin Nucl Med, 37, 29-33. https://doi.org/10.1053/j.semnuclmed.2006.08.001
  17. Keshtgar M, Zaknun JJ, Sabih D, et al (2011). Implementing sentinel lymph node biopsy programs in developing countries: challenges and opportunities. World J Surg, 35, 1159-68. https://doi.org/10.1007/s00268-011-0956-3
  18. Kim T, Giuliano AE, Lyman GH (2006). Lymphatic mapping and sentinel lymph node biopsy in early-stage breast carcinoma: a metaanalysis. Cancer, 106, 4-16. https://doi.org/10.1002/cncr.21568
  19. Krag DN, Anderson SJ, Julian TB, et al (2007). Technical outcomes of sentinel-lymph-node resection and conventional axillary-lymph-node dissection in patients with clinically node-negative breast cancer: results from the NSABP B-32 randomised phase III trial. Lancet Oncol, 8, 881-8. https://doi.org/10.1016/S1470-2045(07)70278-4
  20. Krag DN, Anderson SJ, Julian TB, et al (2010). Sentinel-lymphnode resection compared with conventional axillary-lymphnode dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial. Lancet Oncol, 11, 927-33. https://doi.org/10.1016/S1470-2045(10)70207-2
  21. Krag DN, Ashikaga T, Harlow SP, et al (2009). Surgeon training, protocol compliance, and technical outcomes from breast cancer sentinel lymph node randomized trial. J Natl Cancer Inst, 101, 1356-62. https://doi.org/10.1093/jnci/djp281
  22. Krag DN, Weaver DL, Alex JC, Fairbank JT (1993). Surgical resection and radiolocalization of the sentinel lymph node in breast cancer using a gamma probe. Surg Oncol, 2, 335-9. https://doi.org/10.1016/0960-7404(93)90064-6
  23. Krynyckyi BR, Kim CK, Goyenchea MR, et al (2004). Clinical breast lymphoscintigraphy: optimal techniques for performing studies, image atlas, and analysis of images. Radiographics, 24, 121-45. https://doi.org/10.1148/rg.241025713
  24. Langer I, Guller U, Viehl CT, et al (2009). Axillary lymph node dissection for sentinel lymph node micrometastases may be safely omitted in early-stage breast cancer patients: long-term outcomes of a prospective study. Ann Surg Oncol, 16, 3366-74. https://doi.org/10.1245/s10434-009-0660-9
  25. Leidenius MH, Krogerus LA, Toivonen TS, von Smitten KA (2005). Sentinel node biopsy is not sensible in breast cancer patients with large primary tumours. Eur J Surg Oncol, 31, 364-8. https://doi.org/10.1016/j.ejso.2004.11.006
  26. Lyman GH, Giuliano AE, Somerfield MR, et al (2005). American society of clinical oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer. J Clin Oncol, 23, 7703-20. https://doi.org/10.1200/JCO.2005.08.001
  27. Mansel RE, Fallowfield L, Kissin M, et al (2006). Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: the ALMANAC Trial. J Natl Cancer Inst, 98, 599-609. https://doi.org/10.1093/jnci/djj158
  28. Somasundaram SK, Chicken DW, Waddington WA, et al (2009). Sentinel node imaging in breast cancer using superficial injections: technical details and observations. Eur J Surg Oncol, 35, 1250-6. https://doi.org/10.1016/j.ejso.2009.05.006
  29. Straver ME, Meijnen P, van Tienhoven G, et al (2010). Sentinel node identification rate and nodal involvement in the EORTC 10981-22023 AMAROS trial. Ann Surg Oncol, 17, 1854-61. https://doi.org/10.1245/s10434-010-0945-z
  30. Specht MC, Fey JV, Borgen PI, Cody HS, 3rd (2005). Is the clinically positive axilla in breast cancer really a contraindication to sentinel lymph node biopsy? J Am Coll Surg, 200, 10-4. https://doi.org/10.1016/j.jamcollsurg.2004.09.010
  31. Soran A, Falk J, Bonaventura M, et al (2007). Does failure to visualize a sentinel node on preoperative lymphoscintigraphy predict a greater likelihood of axillary lymph node positivity? J Am Coll Surg, 205, 66-71. https://doi.org/10.1016/j.jamcollsurg.2007.01.064
  32. Truong PT, Lesperance M (2010). Micrometastatic node-positive breast cancer: long-term outcomes and identification of high-risk subsets in a large population-based series. Ann Surg Oncol, 17, 2138-46. https://doi.org/10.1245/s10434-010-0954-y
  33. van der Ploeg IM, Olmos RA, Kroon BB, et al (2009). The hidden sentinel node and SPECT/CT in breast cancer patients. Eur J Nucl Med Mol Imaging, 36, 6-11. https://doi.org/10.1007/s00259-008-0910-2
  34. van der Ploeg IM, Valdes Olmos RA, Kroon BB, Nieweg OE (2008). The Hybrid SPECT/CT as an additional lymphatic mapping tool in patients with breast cancer. World J Surg, 32, 1930-4. https://doi.org/10.1007/s00268-008-9618-5
  35. van der Heiden, van der Loo M, Bezemer PD, et al (2006). Introduction of sentinel node biopsy and stage migration of breast cancer. Eur J Surg Oncol, 32, 710-4. https://doi.org/10.1016/j.ejso.2006.04.001
  36. Veronesi U, Paganelli G, Viale G, et al. (2003). A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer. N Engl J Med, 349, 546-53. https://doi.org/10.1056/NEJMoa012782
  37. Veronesi U, Viale G, Paganelli G, et al (2010). Sentinel lymph node biopsy in breast cancer: ten-year results of a randomized controlled study. Ann Surg, 251, 595-600. https://doi.org/10.1097/SLA.0b013e3181c0e92a
  38. Zavagno G, Del Bianco P, Koussis H, et al (2008). Clinical impact of false-negative sentinel lymph nodes in breast cancer. Eur J Surg Oncol, 34, 620-5. https://doi.org/10.1016/j.ejso.2007.07.003
  39. Zavagno G, De Salvo GL, Scalco G, et al (2008). A Randomized clinical trial on sentinel lymph node biopsy versus axillary lymph node dissection in breast cancer: results of the Sentinella/GIVOM trial. Ann Surg, 247, 207-13. https://doi.org/10.1097/SLA.0b013e31812e6a73

Cited by

  1. Hybrid Imaging in Oncology vol.16, pp.14, 2015, https://doi.org/10.7314/APJCP.2015.16.14.5599
  2. Sentinel Node Biopsy Examination for Breast Cancer in a Routine Laboratory Practice: Results of a Pilot Study vol.17, pp.3, 2016, https://doi.org/10.7314/APJCP.2016.17.3.1149